Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
iStock Rating
B
Details...
Enter Symbol
Oncolytics Biotech, Inc. (NASDAQ: ONCY)
Sector: Medical
Current Price :
$2.64
52 Week Low
$1.72
52 Week High
$4.67
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Press Releases
Media Advisory - Oncolytics Biotech? Inc. to Present at Bank of America Merrill Lynch Health Care Conference
Oncolytics Biotech? Inc. Announces Director Election Results from its Annual and Special Meeting of Shareholders
Oncolytics Biotech? Inc. Announces First Quarter 2013 Results
Oncolytics Biotech? Inc. Announces Details of 2013 Annual and Special Meeting of Shareholders
Media Advisory - Oncolytics Biotech? Inc. to Present at 12th Annual Needham Healthcare Conference
Free Research Reports on FINL, ONCY, PCS and RPRX Issued by the Bedford Report
Oncolytics Biotech? Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN? in Squamous Cell Lung Cancer
Oncolytics Biotech? Inc. Announces 2012 Year End Results
Oncolytics Biotech? Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN? in Non-Small Cell Lung Cancer
Media Advisory - Oncolytics Biotech? Inc. to Present at RBC Capital Markets 2013 Healthcare Conference
Oncolytics Biotech? Inc. Announces Closing of Common Share Offering
Oncolytics Biotech? Inc. Announces Addition to Senior Management Team
Oncolytics Biotech? Inc. Announces Pricing of Common Share Offering
Oncolytics Biotech? Inc. Announces Common Share Offering
Free Research Report on Oncolytics Biotech Inc., Heartware International Inc., Sigma-Aldrich Corp., Carbo Ceramics Inc. and KT Corp.
FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High
Free Research Reports on ONCY, CLSN, ETRM and MOH Issued by the Bedford Report
Oncolytics Biotech? Inc. Announces Additional Positive REOLSYIN? Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung
Oncolytics Biotech? Inc. Announces Positive REOLSYIN? Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium
Biotech Industry Skyrockets in 2012 as FDA New Drug Approval Rate Increases
Free Research Reports on ONCY, RFMD, SCTY and VECO Issued by the Bedford Report
Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN? Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers
Oncolytics Biotech Inc. Announces Addition to Senior Management Team
Oncolytics Biotech? Inc. Collaborators Present Positive REOLYSIN? Trial Results and Research at EORTC-NCI-AACR Symposium
Oncolytics Biotech? Inc. Announces Third Quarter 2012 Results
Oncolytics Biotech? Inc. Completes Patient Enrollment in U.S. Phase II Clinical Trial Investigating REOLYSIN? in Combination with Gemcitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Oncolytics Biotech Inc. Announces the Appointment of Dr. Alan J. Tuchman as Chief Medical Officer
Oncolytics Biotech? Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Squamous Cell Lung Cancer Clinical Trial
Oncolytics Biotech Inc. Provides Update on Phase III Study of REOLYSIN? in Head and Neck Cancers
Oncolytics Biotech? Inc. Completes Patient Enrollment in U.S. Phase I Clinical Trial Investigating REOLYSIN? in Combination with FOLFIRI in Patients with Colorectal Cancer
Oncolytics Biotech? Inc. Completes Patient Enrollment in U.K. Phase I Clinical Trial Investigating REOLYSIN? in Combination with Cyclophosphamide in Patients with Advanced Malignances
Oncolytics Biotech? Inc. Announces Second Quarter 2012 Results
Oncolytics Biotech? Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Advanced and Metastatic Breast Cancers
Oncolytics Announces Independent Data Monitoring Committee Recommends Continued Enrollment in Phase III Study of REOLYSIN? in Head and Neck Cancers Following Review of Safety Data
Media Advisory - Oncolytics Biotech? Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference
Oncolytics Biotech? Inc. Announces Details of 2012 Annual and Special Meeting of Shareholders
Oncolytics Biotech? Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine
Oncolytics Biotech? Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Non-Small Cell Lung Cancer
Oncolytics Biotech? Inc. Announces First Quarter 2012 Results
Oncolytics Biotech? Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Colorectal Cancer
Media Advisory - Oncolytics Biotech? Inc. to Present at 11th Annual Needham Healthcare Conference
Oncolytics Biotech? Inc. Completes Enrollment in First Stage of Phase III Study in Head and Neck Cancers
Oncolytics Biotech? Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
Oncolytics Biotech? Inc. Announces 2011 Year End Results
Media Advisory - Oncolytics Biotech? Inc. to Present at Cowen and Company 32nd Annual Health Care Conference
Oncolytics Biotech? Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer
Oncolytics Biotech? Inc. Closes Bought Deal Financing for Total Gross Proceeds of Cdn$21.3 Million
Oncolytics Biotech? Inc. Announces Phase 2 Clinical Trial of REOLYSIN? in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint
Oncolytics Biotech? Inc. Announces Start of Conformity Testing with SAFC?
Oncolytics Biotech? Inc. Collaborators to Present Positive Phase 2 REOLYSIN Clinical Data in Pancreatic Cancer at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oncolytics Biotech? Inc. Announces Positive Results of U.S. Phase 2 Clinical Trial Investigating REOLYSIN? in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers
Oncolytics Biotech? Inc. to Host Conference Call to Discuss Clinical Data Being Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Oncolytics Biotech? Inc. Announces Third Quarter 2011 Results
Oncolytics Biotech Announces Appointments to Senior Management Team
Media Advisory - Oncolytics Biotech? Inc. to Present at the JMP Securities Healthcare Conference
Media Advisory - Oncolytics Biotech? Inc. to Present at the Wedbush 2011 Life Sciences Management Access Conference
Oncolytics Biotech? Inc. to Present at 31st Canaccord Genuity Growth Conference
Oncolytics Biotech? Inc. Announces Publication of Preclinical Research on Synergistic Combination of Chemotherapy with Oncolytic Virotherapy
Oncolytics Biotech? Inc. Announces Second Quarter 2011 Results
Oncolytics Biotech? Inc. Collaborators Present Positive REOLYSIN? Clinical Trial Results at the 14th World Conference on Lung Cancer
Oncolytics Biotech Announces Appointment of Dr. George M. Gill as Chief Medical Officer
Trade Catalyst: Upcoming Paper to Spotlight Potential of Virus to Treat Certain Lung Cancer Patients
Oncolytics Biotech? Inc. Collaborators to Present Reovirus Research at the 14th World Conference on Lung Cancer
MEDIA ADVISORY - Oncolytics Biotech? Inc. to Present at Jeffries 2011 Global Healthcare Conference
Oncolytics Biotech? Inc. Reports Correction to First Quarter 2011 Results Press Release
Oncolytics Biotech? Inc. Announces First Quarter 2011 Results
Oncolytics Biotech? Inc. Enters into Commercial Supply Agreement with SAFC?
Oncolytics Biotech? Inc. Announces Phase I Multiple Myeloma Cancer Study
Oncolytics Biotech? Inc. Announces Details of 2011 Annual Shareholder Meeting
Oncolytics Biotech? Inc. Announces Positive Data from Translational Clinical Trial Investigating REOLYSIN? in Patients with Metastatic Colorectal Cancer
MEDIA ADVISORY - Oncolytics Biotech? Inc. to Present at 10th Annual Needham Healthcare Conference
Oncolytics Biotech? Inc. Completes Patient Enrollment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN? in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers
Oncolytics Biotech? Inc. Announces 2010 Year End Results
MEDIA ADVISORY - Oncolytics Biotech? Inc. to Present at 31st Annual Cowen and Company Healthcare Conference
Oncolytics Biotech? Inc. Receives $7.7 Million from Exercise of Warrants
MEDIA ADVISORY - Oncolytics Biotech? Inc. to Present at RBC Capital Markets Healthcare Conference
Oncolytics Biotech? Inc. Announces Completion of Enrollment in Translational Clinical Trial Investigating REOLYSIN? in Patients with Metastatic Colorectal Cancer
Oncolytics Biotech(R) Inc. Announces Completion of Enrollment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients With Metastatic Colorectal Cancer
Oncolytics Biotech? Inc. Announces Start of Enrollment in Randomized Phase II Pancreatic Cancer Study
Oncolytics Biotech? Inc. Meets Primary Endpoint for First Part of U.S. Phase 2 Pancreatic Cancer Clinical Trial
MEDIA ADVISORY - Oncolytics Biotech? Inc. to Present at 13th Annual BIO CEO & Investor Conference
Oncolytics Biotech? Inc. Receives US$6.8 Million from Exercise of Warrants
Oncolytics Biotech? Inc. Announces 2-Arm, Randomized Phase II Pancreatic Cancer Study
Oncolytics Biotech? Inc. Announces Opening of Enrollment in U.S. Phase I Colorectal Cancer Study
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##